Drugs / Human Ezrin Peptide 1
Human Ezrin Peptide 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04627233 | Dec 2020 → Mar 2021 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Ezrin Peptide 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04627233 ↗ |
| Known as | Gepon | “An immune-modulatory tetra deca peptide (14-mer peptide) named Human Ezrin Peptide 1 (HEP-1) (trade name Gepon) was introduced by the group of Ataullakhanov in Russia.” NCT04627233 ↗ |
| Known as | HEP1 | “Human Ezrin Peptide 1 (HEP1)” NCT04627233 ↗ |
| Modality | Peptide | “14-mer peptide” NCT04627233 ↗ |
| Route | Subcutaneous | “HEP-1 will be administrated s.c. into the lower abdominal wall” NCT04627233 ↗ |